PrEP

An FDA committee voted 16 to 2 to recommended emitricitabine 200 mg and tenofovir alafenamide 25 mg tablets (Descovy, Gilead) for a HIV pre-exposure prophylaxis indication.

Pre-exposure prophylaxis (PrEP) can reduce the risk of HIV infection in individuals at high risk.

Top news of the day from across the health care landscape.

Administered through a drug-eluting implant, islatravir demonstrated protection against HIV for up to 12 months.

Top news of the day from across the health care landscape.

Health care professionals, including pharmacists and nurse practitioners, play a critical role in attaining goals for reducing HIV transmission.

Due to physician shortages, pharmacists represent a new avenue to increase accessibility to antivirals.

Introduced by U.S. Senator Kamala D. Harris (D-CA), the bill requires all insurance plans to cover HIV prevention medications and services without out-of-pocket costs. The bill also facilitates access to PrEP for uninsured individuals.

Top news of the day from across the health care landscape.

Expansion to adolescents, flexible dosing strategies, innovative delivery models, and long-acting antiretrovirals all help the strategy.

An agreement between the US Department of Health and Human Services and Gilead will provide HIV prevention drugs to uninsured individuals who are at risk.

Top news of the day from across the health care landscape.

Overall, more than half of commercially insured individuals who initiated pre-exposure prophylaxis persisted with it for the 12-month duration of the cohort study.

Vaginal inserts containing tenofovir alafenamide fumarate in combination with elvitegravir were shown to be highly effective in preventing simian/HIV infection in a macaque model.

Many women are unaware of HIV pre-exposure prophylaxis (PrEP) but show a keen interest in spreading the word once they learn about the option, according a recent study in the journal Contraception.

In order for a substantial decrease of HIV infections in the United States, there needs to be a rapid expansion of prevention and treatment for individuals at risk.

Top news of the day across the health care landscape.

To reduce the likelihood of people giving up on PrEP because of difficulty committing to multiple annual visits, a team of investigators created PrEP@Home, a home-based monitoring system that will allow people on the PrEP regimen to meet with their health care providers just once a year, its creators say.

Individuals who perceive themselves to be at a high risk of HIV are more likely to accept pre-exposure prophylaxis (PrEP) than their peers.

A prescription drug ad broadcast during the musical on television has set the stage for a larger conversation about patient access to preexposure prophylaxis medication.

A look at last week's top stories in the world of pharmacy.

New recommendations urge health care providers to offer pre-exposure prophylaxis (PrEP) to individuals at high risk of HIV.

Top news of the day from across the health care landscape.

Several large investigations have demonstrated the considerable efficacy of TDF/FTC taken daily or intermittently, reducing the risk of HIV acquisition by more than 95% in high-risk individuals.

The first study to evaluate population-level roll-out of pre-exposure prophylaxis (PrEP) for HIV in men who have sex with men has demonstrated rapid decline of new HIV infections.

Report analyzes HIV-related stigma among health care providers and the potential impact on quality of patient care.

An interactive text messaging intervention improves pre-exposure prophylaxis (PrEP) adherence in a study of young people at risk for HIV.

Nationwide analysis of Truvada for pre-exposure prophylaxis use finds uptake associated with significant decrease in new HIV infections.

A new study suggests that pre-exposure prophylaxis (PrEP) could also serve as a gateway to primary care services.

Top news of the day from across the health care landscape.